NewAmsterdam Pharma Company NAMS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's financing cash flow?
- NewAmsterdam Pharma Company (NAMS) reported financing cash flow of $11.07M in Q1 2026.
- How has NewAmsterdam Pharma Company's financing cash flow changed year-over-year?
- NewAmsterdam Pharma Company's financing cash flow increased by 69.7% year-over-year, from $6.52M to $11.07M.
- What is the long-term trend for NewAmsterdam Pharma Company's financing cash flow?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's financing cash flow has grown at a -23.2% compound annual growth rate (CAGR), from $84.7M to $29.52M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.